Erudio Healtherudio.com
Sponsor
British Columbia Cancer Agency trials: what clinicians said in public
No HCP commentary report on a trial sponsored by British Columbia Cancer Agency yet. Erudio has found public clinician commentary on 4 clinical trials sponsored by British Columbia Cancer Agency: LUOSICNS, NCT02254785, PROTRACT and SABR-COMET-3. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (British Columbia Cancer Agency). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| SABR-COMET-3 NCT03862911 · British Columbia Cancer Agency DeepView → | oligometastatic cancer (1-3 metastases) | Not applicable | Deep | View | |||
| PROTRACT NCT04015622 · British Columbia Cancer Agency FocusedView → | metastatic castration-resistant prostate cancer post abiraterone | Phase 2 | Focused | View | |||
| LUOSICNS NCT03769103 · British Columbia Cancer Agency FocusedView → | treatment-naïve EGFR-mutated NSCLC with brain metastases | Phase 2 | Focused | View | |||
| NCT02254785 NCT02254785 · British Columbia Cancer Agency FocusedView → | Not given | Phase 2 | Focused | View | |||